Lilly Builds On Gene Therapy Focus With Akouos Takeout

With the planned $487m acquisition of sensorineural-focused Akouos, Lilly makes its second gene therapy M&A play in two years, on top of partnering/financing activity in the space.

Inner ear
Akouos focuses on monogenic inner-ear disease • Source: Shutterstock

More from Deals

More from Business